Agios Announces Key 2025 Milestones for Innovative Rare Disease Portfolio
13 janv. 2025 07h00 HE
|
Agios Pharmaceuticals, Inc.
– FDA Accepted Agios’ Supplemental New Drug Application for PYRUKYND® (mitapivat) in Adult Patients with Non-Transfusion-Dependent and Transfusion-Dependent Alpha- or Beta-Thalassemia; PDUFA Goal Date...
FDA Accepts Agios’ Supplemental New Drug Application for PYRUKYND® (mitapivat) in Adult Patients with Non-Transfusion-Dependent and Transfusion-Dependent Alpha- or Beta-Thalassemia
08 janv. 2025 07h00 HE
|
Agios Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare...
Agios to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025
03 janv. 2025 07h00 HE
|
Agios Pharmaceuticals, Inc.
is scheduled to present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 7:30 a.m. PT / 10:30 a.m. ET.
European Commission Adopts Positive Decision for Orphan Medicinal Product Designation of Agios’ Mitapivat in Sickle Cell Disease
18 déc. 2024 07h00 HE
|
Agios Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare...
Agios Presents Positive Results from Phase 3 ENERGIZE-T Study of Mitapivat at ASH 2024 and Provides Regulatory Update on Mitapivat
08 déc. 2024 12h40 HE
|
Agios Pharmaceuticals, Inc.
– ENERGIZE-T Study Achieved Primary and All Key Secondary Endpoints in Adult Patients with Transfusion-Dependent Alpha- or Beta-Thalassemia – – ENERGIZE-T is First Phase 3 Study to Demonstrate...
Agios to Present New Data on Mitapivat and Tebapivat in Rare Blood Disorders at 66th ASH Annual Meeting and Exposition
05 nov. 2024 09h05 HE
|
Agios Pharmaceuticals, Inc.
Agios announced new data on mitapivat and tebapivat (AG-946) will be featured in oral and poster presentations during the ASH Annual Meeting.
Agios Reports Business Highlights and Third Quarter 2024 Financial Results
31 oct. 2024 06h30 HE
|
Agios Pharmaceuticals, Inc.
Agios reports business highlights and financial results for the third quarter, ended September 30, 2024.
Agios Completes Enrollment of Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease
23 oct. 2024 07h00 HE
|
Agios Pharmaceuticals, Inc.
Agios today announced that enrollment is complete for the Phase 3 RISE UP study in sickle cell disease patients.
Agios to Webcast Conference Call of Third Quarter 2024 Financial Results on October 31, 2024
17 oct. 2024 07h00 HE
|
Agios Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today...
Agios Announces FDA Orphan Drug Designation Granted to Tebapivat (AG-946) for Treatment of Myelodysplastic Syndromes (MDS)
11 sept. 2024 07h00 HE
|
Agios Pharmaceuticals, Inc.
Agios today announced that the FDA has granted orphan drug designation to tebapivat (AG-946) for the treatment of myelodysplastic syndromes (MDS).